[12] Patent
[11] Patent No.:GC0007603  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126156
Date of the Decision to Grant the Patent:18/Apr/2018

[21] Application No.:GC 2014-27370

[22] Filing Date:19/6/2014

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
25/6/2013
61/839,141

[72] Inventors:1- Joseph A. TINO ،2- Anurag S. SRIVASTAVA ،3- Soo Sung Ko ،4- Michael A. GALELLA ،5- Charles M. LANGEVINE ،6- George DELUCCA ،7- Qingjie LIU ،8- Douglas A. BATT،9- Scott Hunter WATTERSON ،10- Qing SHI ،11- Myra BEAUDOIN BERTRAND

[73] Owner: BRISTOL-MYERS SQUIBB COMPANY, Route 206 and Province Line Rd. NJ 08543, Princeton, USA

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.: A61K 31/429, 31/513, 31/517, 31/522; A61P 29/00, 37/00; C07D 403/10, 471/04, 513/04 (2006.01)

[56] Cited Documents:

-WO 2011/159857 A1 (SOUIBB BRISTOL MYERS CO[US]; LIU CHUNJIAN [US]; LIN JAMES [US]; DELUC) 22 December 2011
-US 8 084 620 B2 (LIU OINGJIE [US] ET AL)27 December 2011
-YAN LOU ET AL: Bruton's Tyrosine KinaseInhibitors: Approaches to Potent and Selective Inhibition, Preclinical andClinical Evaluation for InflammatoryDiseases and B Cell Malignancies“, JOURNAL OF MEDICINAL CHEMISTRY,vol. 55, no. 10, 24 May 2012
 
Examiner: PH. Bashair Z. AlEnizi

[54] SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS
[57] Abstract: wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, CN, or CH3; R2 is Cl or CH3; R3 is C(CH3)2OH or CH2CH2OH; Ra is H or CH3; each Rb is independently F, Cl, CH3, and/or OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
No. of claims: 14     No. of figures: 11


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.